CLL
MCID: CHR090
MIFTS: 76

Chronic Lymphocytic Leukemia (CLL) malady

Categories: Rare diseases, Cancer diseases, Genetic diseases, Blood diseases, Immune diseases

Aliases & Classifications for Chronic Lymphocytic Leukemia

Aliases & Descriptions for Chronic Lymphocytic Leukemia:

Name: Chronic Lymphocytic Leukemia 38 12 50 24 24 41 14 69
Cll 12 50 24 66
B-Cell Chronic Lymphocytic Leukemia 12 56 66
Leukemia, Chronic Lymphocytic 24 66 29
B-Cell Chronic Lymphoid Leukemia 12 56
Chronic Lymphatic Leukemia 12 66
Lymphoplasmacytic Leukemia 12 69
Small Lymphocytic Lymphoma 56 69
Leukemia, Lymphocytic, Chronic, B-Cell 42
Familial Chronic Lymphocytic Leukemia 24
Lymphocytic Leukemia Chronic B-Cell 52
Leukemia, Lymphocytic, Chronic 50
Leukemia Lymphocytic Chronic 52
Lymphoma Small Lymphocytic 52
Chronic Lymphoid Leukemia 66
B-Cll 56

Characteristics:

Orphanet epidemiological data:

56
b-cell chronic lymphocytic leukemia
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-5/10000 (Europe),1-9/100000 (France); Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:1040
ICD10 33 C91.1 C91.10
ICD9CM 35 204.1
MeSH 42 D015451
NCIt 47 C3163
Orphanet 56 ORPHA67038
ICD10 via Orphanet 34 C91.1
MESH via Orphanet 43 D015451
UMLS via Orphanet 70 C0023434
MedGen 40 C0023434
UMLS 69 C0023434

Summaries for Chronic Lymphocytic Leukemia

NIH Rare Diseases : 50 chronic lymphocytic leukemia (cll) is a cancer of the lymphocytes (a type of white blood cell) that begins in the stem cells of the bone marrow and then invades the blood. overtime, cll may also spread to the lymph nodes and other organs including the liver, spleen and lungs. it occurs when the stem cells that make lymphocytes become out of control and produce increasing amounts of abnormal lymphocytes (also called leukemic cells). eventually, these abnormal cells replace normal lymphocytes and can crowd out other types of normal blood cells, leading to the features of the condition. early signs and symptoms of cll may include fatigue, weight loss, loss of appetite, fever, night sweats and/or frequent infections. the exact underlying cause of cll is unknown; however, approximately 5% of affected people have other family members with the condition, which suggests there may be a genetic component in rare cases. the best treatment depends on many factors including the stage of the condition, the age of the affected person, the blood cell counts, whether the cll has recurred, and the signs and symptoms present in each person. last updated: 12/27/2014

MalaCards based summary : Chronic Lymphocytic Leukemia, also known as cll, is related to leukemia, chronic lymphocytic 3 and leukemia, chronic lymphocytic 1, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Chronic Lymphocytic Leukemia is CCND1 (Cyclin D1), and among its related pathways/superpathways are MicroRNAs in cancer and Development IGF-1 receptor signaling. The drugs Arzerra and Campath have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

UniProtKB/Swiss-Prot : 66 Leukemia, chronic lymphocytic: A chronic leukemia in which functionally incompetent B-lymphocytes progressively accumulate in the bone marrow, blood, and lymphoid tissues. The clinical evolution of the disorder is heterogeneous, with some patients having indolent disease and others having aggressive disease and short survival.

MedlinePlus : 41 leukemia is cancer of the white blood cells. white blood cells help your body fight infection. your blood cells form in your bone marrow. in leukemia, the bone marrow produces abnormal white blood cells. these cells crowd out the healthy blood cells, making it hard for blood to do its work. in chronic lymphocytic leukemia (cll), there are too many lymphocytes, a type of white blood cell. cll is the second most common type of leukemia in adults. it often occurs during or after middle age, and is rare in children. usually cll does not cause any symptoms. if you have symptoms, they may include painless swelling of the lymph nodes in the neck, underarm, stomach, or groin fatigue pain or a feeling of fullness below the ribs fever and infection weight loss tests that examine the blood, bone marrow, and lymph nodes diagnose cll. your doctor may choose to just monitor you until symptoms appear or change. treatments include radiation therapy, chemotherapy, surgery to remove the spleen, and targeted therapy. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

Disease Ontology : 12 A lymphoblastic leukemia characterized by over production of B-cells and their accumulation in bone marrow and blood.

Wikipedia : 71 B-cell chronic lymphocytic leukemia (B-CLL), also known as chronic lymphoid leukemia (CLL), is the most... more...

Related Diseases for Chronic Lymphocytic Leukemia

Diseases in the Acute Lymphocytic Leukemia family:

Leukemia, Chronic Lymphocytic 3 Leukemia, Chronic Lymphocytic 1
Leukemia, Chronic Lymphocytic 2 Adult Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia

Diseases related to Chronic Lymphocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 277)
id Related Disease Score Top Affiliating Genes
1 leukemia, chronic lymphocytic 3 12.1
2 leukemia, chronic lymphocytic 1 12.1
3 leukemia, chronic lymphocytic 2 12.1
4 postgerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 12.0
5 pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 12.0
6 cll/sll 11.8
7 t-cell prolymphocytic leukemia 11.7
8 leukemia 11.7
9 richter's syndrome 11.3
10 prolymphocytic leukemia 11.3
11 hairy cell leukemia 11.3
12 immunotactoid glomerulopathy 11.2
13 leukemia, b-cell, chronic 11.0
14 t-cell large granular lymphocyte leukemia 10.9
15 immunotactoid or fibrillary glomerulopathy 10.9
16 lymphoma 10.7
17 barnicoat baraitser syndrome 10.5 CD38 CD5 FCER2 MS4A1 TP53 ZAP70
18 duodenal ulcer 10.5 ATM CD38 CD5 TP53
19 hyperaldosteronism, familial, type ii 10.5 CD38 CD5 FCER2 MS4A1 ZAP70
20 seminal vesicle chronic gonorrhea 10.5 ATM CCND1 CD38 CD5 FCER2 ZAP70
21 melanoma metastasis 10.5 ATM BCL2 CCND1 CD5 MCL1 TP53
22 villoglandular endometrial endometrioid adenocarcinoma 10.5 ATM CCND1 TP53
23 gingival recession 10.5 BCL2 CCND1 MCL1 MS4A1
24 his bundle tachycardia 10.4 BCL2 CCND1 TP53
25 microcystic adenoma 10.4 BCL2 CCND1 CD5
26 male infertility 10.4 BCL2 CCND1
27 childhood brain stem glioma 10.4 ATM CCND1 CD38 CD5 PAX5 TP53
28 statin toxicity 10.4 BCL2 CCND1 TP53
29 cleft palate cardiac defect ectrodactyly 10.4 BCL2 CCND1 TP53
30 pulmonary fibrosis, idiopathic 10.4 ATM BCL2 CCND1 CD38 CD5 FCER2
31 primary tubular proximal acidosis 10.4 BCL2 IGHM PAX5
32 angiosarcoma 10.4 IGHM PAX5 ZAP70
33 ectodermal dysplasia 10.4 BCL2 CCND1 CD5 PAX5 TP53
34 bladder disease 10.4 BCL2 CCND1 CD5 MS4A1 PAX5 TP53
35 cutis laxa, autosomal recessive, type ib 10.4 CCND1 CD38 MCL1 TP53
36 theileriasis 10.4 CCND1 CD38 CD5
37 uterine ligament endometrioid adenocarcinoma 10.4 CCND1 CD5 PAX5
38 marantic endocarditis 10.4 ATM BCL2 CCND1 MS4A1 PAX5
39 coloboma of iris 10.4 IGHM MS4A1
40 hemolytic anemia 10.4
41 cecum adenoma 10.3 BCL2 CCND1 TP53
42 autoimmune hemolytic anemia 10.3
43 mesothelioma, somatic 10.3 BCL2 CCND1 CD5
44 hodgkin lymphoma 10.3
45 nasopharyngeal carcinoma 10.3 ATM BCL2 TP53
46 mantle cell lymphoma 10.2
47 fetal nicotine spectrum disorder 10.2 IKZF3 PAX5
48 b-cell lymphomas 10.2
49 endotheliitis 10.2
50 multiple myeloma 10.2

Graphical network of the top 20 diseases related to Chronic Lymphocytic Leukemia:



Diseases related to Chronic Lymphocytic Leukemia

Symptoms & Phenotypes for Chronic Lymphocytic Leukemia

UMLS symptoms related to Chronic Lymphocytic Leukemia:


angina pectoris, chest pain, edema, fatigue

GenomeRNAi Phenotypes related to Chronic Lymphocytic Leukemia according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 ATM BCL2 FCER2 MCL1 POT1 TP53
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 ATM BCL2 MCL1 POT1 TP53
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 ATM BCL2 CCND1 CD38 MCL1 POT1

MGI Mouse Phenotypes related to Chronic Lymphocytic Leukemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.97 ATM BCL2 CCND1 CD38 CD5 FCER2
2 immune system MP:0005387 9.77 IKZF3 MCL1 MS4A1 P2RX7 PAX5 TP53
3 integument MP:0010771 9.23 ATM BCL2 CCND1 CD5 MCL1 P2RX7

Drugs & Therapeutics for Chronic Lymphocytic Leukemia

FDA approved drugs:

(show all 9)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Arzerra 17 46 OFATUMUMAB GlaxoSmithKline Approved October 2009
2
Campath 17 46 ALEMTUZUMAB Berlex Laboratories Approved May 2001
3
Clolar 17 46 CLOFARABINE Genzyme Approved December, 2004
4
Gazyva 17 46 OBINUTUZUMAB Genentech Approved October of 2013
5
Imbruvica 17 46 IBRUTINIB Pharmacyclics Approved November of 2013/Approved February 2014
6
Revlimid 17 46 LENALIDOMIDE Celgene Approved June 2013
7
Rituxan 17 46 RITUXIMAB Biogen IDEC, Genentech Approved November 1997
8
Treanda 17 46 BENDAMUSTINE HYDROCHLORIDE Cephalon Approved October 2008
9
Zydelig 17 46 IDELALISIB Gilead Approved July 2014

Drugs for Chronic Lymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 604)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-61-7 60961
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
3
Pentostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53910-25-1 40926 439693
4
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
5
Chlorambucil Approved Phase 4,Phase 3,Phase 2,Phase 1 305-03-3 2708
6
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
7
Vidarabine Approved Phase 4,Phase 3,Phase 2,Phase 1 24356-66-9 32326 21704
8
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
9
Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
10
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
11
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
12
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
13
Busulfan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 55-98-1 2478
14
Valganciclovir Approved, Investigational Phase 4,Phase 2 175865-60-8 64147
15
Menthol Approved Phase 4 2216-51-5 16666
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
17
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 54575, 6560146 143
18 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
21 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
25 Imatinib Mesylate Phase 4,Phase 3,Phase 2,Phase 1 123596
26 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Bendamustine Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
30 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
31 Antibodies Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
32 Antibodies, Monoclonal Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
33 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
34 Vaccines Phase 4,Phase 3,Phase 1,Phase 2
35 Epoetin alfa Phase 4,Phase 3,Phase 2,Phase 1 113427-24-0
36 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
37 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1
38 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
39 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
40 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
41 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
45 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
47 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1
48 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 1955)
id Name Status NCT ID Phase
1 Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4
2 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4
3 Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America Completed NCT02559583 Phase 4
4 Antiviral Treatment of Chronic Lymphocytic Leukemia Completed NCT01255644 Phase 4
5 A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) Completed NCT01056510 Phase 4
6 A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4
7 Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL) Completed NCT00802737 Phase 4
8 A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status Completed NCT01271010 Phase 4
9 A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status Completed NCT01283386 Phase 4
10 The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL Completed NCT00919321 Phase 4
11 Effect of Epoetin Alfa on Hemoglobin, Symptom Distress, and Quality of Life in Patients Receiving Chemotherapy Completed NCT00524407 Phase 4
12 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
13 Low Grade Lymphoma Recruiting NCT01698866 Phase 4
14 Rituximab (RTX) Therapy in Patients With Active TAO Recruiting NCT02378298 Phase 4
15 ALL SCTped FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
16 A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B Terminated NCT02608060 Phase 4
17 A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia Withdrawn NCT01739491 Phase 4
18 Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia Unknown status NCT01670812 Phase 3
19 Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia Unknown status NCT01657955 Phase 3
20 Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia Unknown status NCT00017108 Phase 3
21 The Effect of 25-OH-Vitamin-D3 Substitution in Patients With Malignant and Immune-hematologic Diseases Unknown status NCT01518959 Phase 3
22 30Gy Versus 40Gy Involved-field Radiotherapy for Localized Diffuse Large B Cell Lymphoma Achieving CR After Chemotherapy Unknown status NCT01156259 Phase 3
23 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3
24 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
25 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
26 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
27 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3
28 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
29 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
30 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
31 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3
32 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3
33 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
34 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423747 Phase 3
35 ALL-SCT BFM International- HSCT in Children and Adolescents With ALL Unknown status NCT01423500 Phase 3
36 Unrelated Double Umbilical Cord Blood Units Transplantation Unknown status NCT01015742 Phase 2, Phase 3
37 Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia Completed NCT00276848 Phase 3
38 Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia Completed NCT00931645 Phase 3
39 Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia Completed NCT00262782 Phase 3
40 Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Completed NCT00262795 Phase 3
41 Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL) Completed NCT01423032 Phase 2, Phase 3
42 Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia Completed NCT01500083 Phase 3
43 Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia Completed NCT00281892 Phase 3
44 A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) Completed NCT01580228 Phase 3
45 A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) Completed NCT01539512 Phase 3
46 Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Completed NCT00086580 Phase 3
47 FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients Completed NCT00090051 Phase 3
48 Fludarabine, Cyclophosphamide, and Rituximab Followed by Rituximab or Observation in Older Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia Completed NCT00645606 Phase 3
49 Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Completed NCT00024440 Phase 3
50 Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia Completed NCT00275054 Phase 3

Search NIH Clinical Center for Chronic Lymphocytic Leukemia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Chronic Lymphocytic Leukemia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: leukemia, lymphocytic, chronic, b-cell

Genetic Tests for Chronic Lymphocytic Leukemia

Genetic tests related to Chronic Lymphocytic Leukemia:

id Genetic test Affiliating Genes
1 Chronic Lymphocytic Leukemia 29 24
2 Leukemia, Chronic Lymphocytic 24 CCND1

Anatomical Context for Chronic Lymphocytic Leukemia

MalaCards organs/tissues related to Chronic Lymphocytic Leukemia:

39
B Cells, Bone, Bone Marrow, Lymph Node, T Cells, Spleen, Testes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Chronic Lymphocytic Leukemia:
id Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease
3 Blood Hematopoietic Bone Marrow Small Pre B-Cells Affected by disease

Publications for Chronic Lymphocytic Leukemia

Articles related to Chronic Lymphocytic Leukemia:

(show top 50) (show all 2766)
id Title Authors Year
1
Infectious complications in chronic lymphocytic leukemia- a retrospective analysis: single institution experience. ( 28503927 )
2017
2
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. ( 28077600 )
2017
3
State of the Art in MicroRNA as Diagnostic and Therapeutic Biomarkers in Chronic Lymphocytic Leukemia. ( 28084621 )
2017
4
Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. ( 28526063 )
2017
5
Using Murine Models to Investigate Tumor-Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma. ( 28512625 )
2017
6
Treatment of chronic lymphocytic leukemia in older adults. ( 28487078 )
2017
7
Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era. ( 28499646 )
2017
8
Plasma matrix metalloprotease 9 correlates with blood lymphocytosis, leukemic cell invasiveness, and prognosis in B-cell chronic lymphocytic leukemia. ( 28240053 )
2017
9
Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia. ( 28509580 )
2017
10
The Expression of Toll-Like Receptors in Patients with B-Cell Chronic Lymphocytic Leukemia. ( 28083607 )
2017
11
Obinutuzumab is Effective in Chronic Lymphocytic Leukemia and Rheumatoid Arthritis After Rituximab Failure: A Case Report. ( 28487504 )
2017
12
Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia. ( 28503240 )
2017
13
Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment. ( 28088788 )
2017
14
Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia. ( 28062113 )
2017
15
Bilateral Chylothorax Complicating a Case of Chronic Lymphocytic Leukemia: A Case Report. ( 28484586 )
2017
16
NF-I_B p50 (nfkb1) contributes to pathogenesis in the EI1-TCL1 mouse model of chronic lymphocytic leukemia. ( 28515090 )
2017
17
An unusual case of chronic diarrhea: chronic lymphocytic leukemia/small lymphocytic lymphoma with colorectal involvement. ( 28511955 )
2017
18
Venetoclax for the treatment of patients with chronic lymphocytic leukemia. ( 28492339 )
2017
19
IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia. ( 28517553 )
2017
20
The use of inexpensive broad spectrum lower toxicity therapeutics in chronic lymphocytic leukemia. ( 28534346 )
2017
21
Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia: Implication for therapy. ( 28053325 )
2017
22
Learning from the Failures of Drug Discovery in B-Cell Non-Hodgkin Lymphomas and Perspectives for the Future: Chronic Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma as Two Ends of a Spectrum in Drug Development. ( 28494631 )
2017
23
Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ ATM FISH deletions. ( 28493833 )
2017
24
Two Distinct BCL2 Rearrangements, Each Observed in 2 Independent Subclones, Evolving from a Founder Clone with Trisomy 12 in a Unique Case of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 28514780 )
2017
25
PPAR-delta promotes survival of chronic lymphocytic leukemia cells in energetically unfavorable conditions. ( 28050012 )
2017
26
Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia. ( 28091403 )
2017
27
Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib. ( 27756158 )
2017
28
Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia. ( 27757836 )
2017
29
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. ( 28049639 )
2017
30
Synthetic high-density lipoproteins as targeted monotherapy for chronic lymphocytic leukemia. ( 28061439 )
2017
31
Receptor tyrosine kinase-like orphan receptor 1 (ROR-1): An emerging target for diagnosis and therapy of chronic lymphocytic leukemia. ( 28160756 )
2017
32
Chronic Lymphocytic Leukemia: Individualizing Treatment Approach. ( 28515252 )
2017
33
The distribution and potential prognostic value of SMAD protein expression in chronic lymphocytic leukemia. ( 28349818 )
2017
34
Feasibility of Lenalidomide Therapy for Persistent Chronic Lymphocytic Leukemia after Allogeneic Transplantation. ( 28495642 )
2017
35
From genome to proteome: Looking beyond DNA and RNA in chronic lymphocytic leukemia. ( 28069558 )
2017
36
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 28073846 )
2017
37
High-resolution melting analysis for rapid and sensitive NOTCH1 screening in chronic lymphocytic leukemia. ( 28075457 )
2017
38
Dynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts. ( 28496009 )
2017
39
A Systemic Capillary Leak Syndrome (Clarkson Syndrome) in a Patient with Chronic Lymphocytic Leukemia: A Case Report in an Out-of-Hospital Setting. ( 27069700 )
2016
40
Circulating microRNA-192 as a diagnostic biomarker in human chronic lymphocytic leukemia. ( 27659777 )
2016
41
Development of a Flow Cytometric Method for Quantification of BCL-2 Family Members in Chronic Lymphocytic Leukemia and Correlation with Sensitivity to BCL-2 Family Inhibitors. ( 27177607 )
2016
42
The expression of endothelin-1 in chronic lymphocytic leukemia is controlled by epigenetic mechanisms and extracellular stimuli. ( 28092772 )
2016
43
Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. ( 27660167 )
2016
44
Effective mitigation of tumor lysis syndrome with gradual venetoclax dose ramp, prophylaxis, and monitoring in patients with chronic lymphocytic leukemia. ( 27179967 )
2016
45
Practical approach to management of chronic lymphocytic leukemia. ( 27186193 )
2016
46
Rapidly Fatal Dissemination of Merkel Cell Carcinoma in a Patient Treated with Alemtuzumab for Chronic Lymphocytic Leukemia. ( 27509643 )
2016
47
UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia? ( 26589911 )
2016
48
Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. ( 26675346 )
2016
49
Oral Cryptococcosis in a Patient with Chronic Lymphocytic Leukemia. ( 27425164 )
2016
50
Chronic lymphocytic leukemia in association with a ranula: a report and review of the literature. ( 28089461 )
2016

Variations for Chronic Lymphocytic Leukemia

ClinVar genetic disease variations for Chronic Lymphocytic Leukemia:

6 (show top 50) (show all 93)
id Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
2 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
3 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
4 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
5 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
6 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
7 BRAF NM_004333.4(BRAF): c.1391G> A (p.Gly464Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913348 GRCh37 Chromosome 7, 140481417: 140481417
8 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
9 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154
10 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
11 MYD88 NM_001172567.1(MYD88): c.818T> C (p.Leu273Pro) single nucleotide variant Pathogenic/Likely pathogenic rs387907272 GRCh37 Chromosome 3, 38182641: 38182641
12 BRAF NM_004333.4(BRAF): c.1780G> A (p.Asp594Asn) single nucleotide variant Pathogenic/Likely pathogenic rs397516896 GRCh37 Chromosome 7, 140453155: 140453155
13 BRAF NM_004333.4(BRAF): c.1802A> C (p.Lys601Thr) single nucleotide variant Pathogenic/Likely pathogenic rs397507484 GRCh37 Chromosome 7, 140453133: 140453133
14 KRAS NM_033360.3(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 GRCh37 Chromosome 12, 25380275: 25380275
15 FBXW7 NM_033632.3(FBXW7): c.1513C> T (p.Arg505Cys) single nucleotide variant Likely pathogenic rs149680468 GRCh37 Chromosome 4, 153247289: 153247289
16 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
17 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
18 PTPN11 NM_002834.4(PTPN11): c.214G> A (p.Ala72Thr) single nucleotide variant Likely pathogenic rs121918453 GRCh38 Chromosome 12, 112450394: 112450394
19 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh38 Chromosome 11, 534285: 534285
20 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
21 TP53 NM_000546.5(TP53): c.578A> T (p.His193Leu) single nucleotide variant Likely pathogenic rs786201838 GRCh37 Chromosome 17, 7578271: 7578271
22 TP53 NM_000546.5(TP53): c.824G> A (p.Cys275Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs863224451 GRCh38 Chromosome 17, 7673796: 7673796
23 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic/Likely pathogenic rs760043106 GRCh38 Chromosome 17, 7674947: 7674947
24 TP53 NM_000546.5(TP53): c.818G> C (p.Arg273Pro) single nucleotide variant Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
25 TP53 NM_000546.5(TP53): c.743G> T (p.Arg248Leu) single nucleotide variant Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
26 TP53 NM_000546.5(TP53): c.577C> T (p.His193Tyr) single nucleotide variant Likely pathogenic rs876658468 GRCh37 Chromosome 17, 7578272: 7578272
27 TP53 NM_000546.5(TP53): c.743G> C (p.Arg248Pro) single nucleotide variant Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
28 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
29 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs121913255 GRCh37 Chromosome 1, 115256528: 115256528
30 NRAS NM_002524.4(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
31 BRAF NM_004333.4(BRAF): c.1780G> C (p.Asp594His) single nucleotide variant Pathogenic/Likely pathogenic rs397516896 GRCh37 Chromosome 7, 140453155: 140453155
32 SF3B1 NM_012433.3(SF3B1): c.1996A> G (p.Lys666Glu) single nucleotide variant Likely pathogenic rs754688962 GRCh37 Chromosome 2, 198267361: 198267361
33 HRAS; LRRC56 NM_005343.3(HRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Likely pathogenic rs121913233 GRCh37 Chromosome 11, 533874: 533874
34 BTK NM_000061.2(BTK): c.1441T> A (p.Cys481Ser) single nucleotide variant Likely pathogenic rs1057519826 GRCh37 Chromosome X, 100611165: 100611165
35 PLCG2 NM_002661.4(PLCG2): c.1993C> T (p.Arg665Trp) single nucleotide variant Likely pathogenic rs1057519831 GRCh37 Chromosome 16, 81946260: 81946260
36 PLCG2 NM_002661.4(PLCG2): c.2535A> C (p.Leu845Phe) single nucleotide variant Likely pathogenic rs1057519832 GRCh37 Chromosome 16, 81962183: 81962183
37 PLCG2 NM_002661.4(PLCG2): c.2535A> T (p.Leu845Phe) single nucleotide variant Likely pathogenic rs1057519832 GRCh37 Chromosome 16, 81962183: 81962183
38 BRAF NM_004333.4(BRAF): c.1803A> C (p.Lys601Asn) single nucleotide variant Likely pathogenic rs121913365 GRCh37 Chromosome 7, 140453132: 140453132
39 HRAS; LRRC56 NM_005343.3(HRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Likely pathogenic rs121913233 GRCh37 Chromosome 11, 533874: 533874
40 FBXW7 NM_033632.3(FBXW7): c.1393C> T (p.Arg465Cys) single nucleotide variant Likely pathogenic rs867384286 GRCh37 Chromosome 4, 153249385: 153249385
41 FBXW7 NM_033632.3(FBXW7): c.1394G> A (p.Arg465His) single nucleotide variant Likely pathogenic rs1057519895 GRCh37 Chromosome 4, 153249384: 153249384
42 FBXW7 NM_033632.3(FBXW7): c.1394G> C (p.Arg465Pro) single nucleotide variant Likely pathogenic rs1057519895 GRCh37 Chromosome 4, 153249384: 153249384
43 FBXW7 NM_033632.3(FBXW7): c.1394G> T (p.Arg465Leu) single nucleotide variant Likely pathogenic rs1057519895 GRCh37 Chromosome 4, 153249384: 153249384
44 FBXW7 NM_033632.3(FBXW7): c.1393C> G (p.Arg465Gly) single nucleotide variant Likely pathogenic rs867384286 GRCh37 Chromosome 4, 153249385: 153249385
45 FBXW7 NM_033632.3(FBXW7): c.1513C> G (p.Arg505Gly) single nucleotide variant Likely pathogenic rs149680468 GRCh37 Chromosome 4, 153247289: 153247289
46 FBXW7 NM_033632.3(FBXW7): c.1514G> T (p.Arg505Leu) single nucleotide variant Likely pathogenic rs1057519896 GRCh37 Chromosome 4, 153247288: 153247288
47 FBXW7 NM_033632.3(FBXW7): c.1514G> A (p.Arg505His) single nucleotide variant Likely pathogenic rs1057519896 GRCh37 Chromosome 4, 153247288: 153247288
48 FBXW7 NM_033632.3(FBXW7): c.1513C> A (p.Arg505Ser) single nucleotide variant Likely pathogenic rs149680468 GRCh38 Chromosome 4, 152326137: 152326137
49 HRAS; LRRC56 NM_005343.3(HRAS): c.38G> C (p.Gly13Ala) single nucleotide variant Likely pathogenic rs104894226 GRCh37 Chromosome 11, 534285: 534285
50 HRAS; LRRC56 NM_005343.3(HRAS): c.181C> G (p.Gln61Glu) single nucleotide variant Likely pathogenic rs28933406 GRCh38 Chromosome 11, 533875: 533875

Copy number variations for Chronic Lymphocytic Leukemia from CNVD:

7 (show top 50) (show all 1219)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14042 1 103366560 104230405 Loss Chronic lymphocytic leukemia
2 14895 1 110954839 111582296 Loss Chronic lymphocytic leukemia
3 14947 1 111421057 111642223 Loss Chronic lymphocytic leukemia
4 15456 1 115719205 117399077 Loss Chronic lymphocytic leukemia
5 17206 1 141510591 145121245 Deletion Chronic lymphocytic leukemia
6 17207 1 141510591 145121245 Loss Chronic lymphocytic leukemia
7 18527 1 146265358 148164994 Gain Chronic lymphocytic leukemia
8 19758 1 151208615 155645185 Gain Chronic lymphocytic leukemia
9 20025 1 152611898 157344161 Loss Chronic lymphocytic leukemia
10 21378 1 158336749 159355008 Loss Chronic lymphocytic leukemia
11 21384 1 158391645 159433573 Loss Chronic lymphocytic leukemia
12 21385 1 158391645 189498990 Loss Chronic lymphocytic leukemia
13 23023 1 170758115 170759115 Loss Chronic lymphocytic leukemia
14 23030 1 170822660 170823660 Gain Chronic lymphocytic leukemia
15 23626 1 172107770 172108770 Gain Chronic lymphocytic leukemia
16 24171 1 176708253 177307399 Gain Chronic lymphocytic leukemia
17 25274 1 186459864 186720923 Loss Chronic lymphocytic leukemia
18 25359 1 187890295 188217703 Loss Chronic lymphocytic leukemia
19 25435 1 189143434 189363313 Gain Chronic lymphocytic leukemia
20 25473 1 189804292 192389810 Gain Chronic lymphocytic leukemia
21 25685 1 193314169 193528753 Gain Chronic lymphocytic leukemia
22 26789 1 202768030 203457313 Loss Chronic lymphocytic leukemia
23 26818 1 203067017 205298659 Loss Chronic lymphocytic leukemia
24 26975 1 204424298 206588789 Loss Chronic lymphocytic leukemia
25 28076 1 218313329 220732423 Loss Chronic lymphocytic leukemia
26 28130 1 218942571 219164038 Loss Chronic lymphocytic leukemia
27 28133 1 218959043 244561923 Loss Chronic lymphocytic leukemia
28 28265 1 220678511 222112407 Gain Chronic lymphocytic leukemia
29 28321 1 221304071 221582122 Gain Chronic lymphocytic leukemia
30 28577 1 223594083 225234079 Loss Chronic lymphocytic leukemia
31 28643 1 224353010 225571533 Loss Chronic lymphocytic leukemia
32 28702 1 224857883 233411748 Loss Chronic lymphocytic leukemia
33 29066 1 227299711 227518155 Loss Chronic lymphocytic leukemia
34 29113 1 227696842 233631743 Loss Chronic lymphocytic leukemia
35 29265 1 229664393 229947546 Gain Chronic lymphocytic leukemia
36 29501 1 232707626 233302391 Loss Chronic lymphocytic leukemia
37 31053 1 24943712 26054939 Loss Chronic lymphocytic leukemia
38 31193 1 25985121 29490451 Deletion Chronic lymphocytic leukemia
39 31425 1 27504484 28494376 Loss Chronic lymphocytic leukemia
40 32443 1 36783544 38823237 Loss Chronic lymphocytic leukemia
41 33495 1 45606989 46307302 Gain Chronic lymphocytic leukemia
42 34016 1 51545765 53346467 Loss Chronic lymphocytic leukemia
43 34255 1 54029769 55100800 Loss Chronic lymphocytic leukemia
44 34911 1 57712092 58034742 Gain Chronic lymphocytic leukemia
45 35379 1 62697088 63142732 Loss Chronic lymphocytic leukemia
46 35406 1 63335974 63596958 Gain Chronic lymphocytic leukemia
47 35407 1 63335974 63641668 Gain Chronic lymphocytic leukemia
48 36497 1 76364563 76710672 Loss Chronic lymphocytic leukemia
49 36890 1 82341866 82576806 Loss Chronic lymphocytic leukemia
50 36895 1 82581235 82812961 Loss Chronic lymphocytic leukemia

Expression for Chronic Lymphocytic Leukemia

Search GEO for disease gene expression data for Chronic Lymphocytic Leukemia.

Pathways for Chronic Lymphocytic Leukemia

Pathways related to Chronic Lymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 22)
id Super pathways Score Top Affiliating Genes
1 12.33 ATM BCL2 CCND1 MCL1 TP53
2
Show member pathways
12.28 CCND1 FCER2 IGHG1 TP53
3 12.17 BCL2 CD38 FCER2 TP53
4
Show member pathways
12.12 ATM BCL2 CCND1 TP53
5 12 ATM BCL2 CCND1 TP53
6 11.91 ATM BCL2 CCND1 TP53
7 11.77 ATM BCL2 CCND1 TP53
8 11.76 ATM BCL2 ZAP70
9 11.7 BCL2 CCND1 TP53
10 11.66 CD38 CD5 FCER2 MS4A1
11 11.65 BCL2 CCND1 PAX5
12 11.62 ATM BCL2 TP53
13 11.56 ATM CCND1 POT1
14 11.41 ATM CCND1 TP53
15 11.36 ATM BCL2 TP53
16 11.31 ATM CCND1 TP53
17 11.16 BCL2 CCND1 MCL1 TP53
18 11.16 BCL2 CCND1 FCER2 IGHG1 MCL1 TP53
19 11.11 ATM CCND1 TP53
20 11.08 CD38 CD5 FCER2 MS4A1 PAX5
21 10.84 ATM BCL2 MCL1
22
Show member pathways
10.78 ATM BCL2 TP53

GO Terms for Chronic Lymphocytic Leukemia

Cellular components related to Chronic Lymphocytic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.1 CD5 FCER2 IGHG1 IGHM MS4A1 P2RX7

Biological processes related to Chronic Lymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 16)
id Name GO ID Score Top Affiliating Genes
1 apoptotic signaling pathway GO:0097190 9.63 CD38 CD5 P2RX7
2 response to cytokine GO:0034097 9.58 BCL2 CD38 MCL1
3 negative regulation of anoikis GO:2000811 9.56 BCL2 MCL1
4 negative regulation of telomerase activity GO:0051974 9.55 POT1 TP53
5 determination of adult lifespan GO:0008340 9.54 ATM TP53
6 humoral immune response GO:0006959 9.54 BCL2 MS4A1 PAX5
7 oocyte development GO:0048599 9.52 ATM BCL2
8 negative regulation of bone resorption GO:0045779 9.51 CD38 P2RX7
9 replicative senescence GO:0090399 9.49 ATM TP53
10 regulation of mitochondrial membrane permeability GO:0046902 9.48 BCL2 TP53
11 mitotic G1 DNA damage checkpoint GO:0031571 9.43 CCND1 TP53
12 response to gamma radiation GO:0010332 9.43 BCL2 TP53 TRIM13
13 regulation of apoptotic process GO:0042981 9.35 ATM BCL2 IKZF3 MCL1 TP53
14 B cell activation GO:0042113 9.33 IKZF3 MS4A1 ZAP70
15 regulation of telomere maintenance via telomerase GO:0032210 9.32 ATM POT1
16 B cell receptor signaling pathway GO:0050853 8.92 BCL2 CD38 IGHG1 IGHM

Molecular functions related to Chronic Lymphocytic Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 ATM BCL2 CCND1 CD5 FCER2 IGHG1
2 channel activity GO:0015267 9.16 BCL2 P2RX7
3 BH3 domain binding GO:0051434 8.62 BCL2 MCL1

Sources for Chronic Lymphocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....